A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Richmond University Medical Center, Staten Island

Roswell Park Cancer Institute, Buffalo

Oncology/Hematology Associates, Bethlehem

Gerogetown University Lombardi Cancer Center, Washington D.C.

UNC School of Medicine, Chapel Hill

H. Lee Moffitt Cancer Center, Tampa

Oncology Specialists, Park Ridge

Highlands Oncology Group, Fayetteville

Arlington Cancer Center, Arlington

Nevada Cancer Institute, Las Vegas

Comprehensive Cancer Care, Los Angeles

Cancer Care Associates Medical Group, Inc., Redondo Beach

North Valley Hematology/Oncology Medical Group: The Thomas & Dorothy Leavey Cancer Center, Northridge

UCSD - Moores Cancer Center, La Jolla

Comprehensive nBlood and Cancer Care, Bakersfield

Norwalk Hospital, Norwalk